美股
Lead report
Taysha Gene Therapies Plunges on $200M Stock Offering at $6 Per Share
Taysha Gene Therapies announced a $200 million public offering at $6 per share, causing a sharp after-hours selloff. The article analyzes the dilutive financing, pipeline progress, and investor concerns.
